SUNDAY, JULY 15, 2018

Long-acting injectable effective against vaginal HIV transmissions

Scientists from the University of North Carolina School of Medicine have conducted a study to show that long-lasting injections containing an HIV drug provide people with protection against HIV transmissions. Read More »

Study reveals HIV targets tissue macrophages

A team of researchers in the Division of Infectious Diseases at the University of North Carolina School of Medicine recently found that human immunodeficiency virus (HIV) infections target tissue macrophages, which are large white blood cells located in the brain, liver and connective tissues. Read More »

Antiretroviral therapy decreases HIV infections in female reproductive tract

Scientists recently evaluated for the first time exactly how antiretroviral therapy (ART) changes HIV dissemination and infection within the reproductive tracts of women. Read More »

Medicago to create monoclonal antibodies for Ebola

Medicago, a top Canadian company that develops and manufactures plant-based vaccines and therapeutics, recently earned a contract from the Public Health Agency of Canada to create monoclonal antibodies for Ebola. Read More »

DART protein molecule shows promise against HIV

A molecule recently developed by Duke Medicine, the University of North Carolina at Chapel Hill and MacroGenics, Inc., referred to as DART, has proven to have the ability to bind HIV-infected cells to the immune system’s killer T-cells. DART stands for Dual-Affinity Re-Targeting protein and is a type of bi-specific antibody. Read More »

Translucent fish larvae allow scientists to view progression of meningitis infection

Researchers from Duke University Medical Center recently developed a new method to witness how cryptococcal meningitis infections take over the brain, a process that kills roughly 600,000 people each year, by watching the progression in infected zebra fish larvae, whose bodies are translucent. Read More »

PRA Health, Alliance for Multispecialty Research team up on vaccines

PRA Health Sciences (PRA) and the Alliance for Multispecialty Research (AMR) have teamed up to get new vaccines to market more quickly. "This is an ideal collaboration," Frank Hijek, PRA's senior vice president for strategic drug development, said. Read More »

Cell phones monitor flu on campus

Researchers use mobile app to track spread of influenza from person to person Read More »

Vomiting device to detect aerosolized virus particles

A team of researchers at North Carolina State University and Wake Forest University has developed a vomiting device to provide direct evidence that aerosolized virus particles like human norovirus can come from vomiting. Read More »

Argos to present on HIV treatment at conference

Argos Therapeutics Inc., a biopharmaceutical company, recently announced that company representatives will give a presentation at the eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Read More »

Researchers find Dengue virus mutates as it spreads

Researchers recently discovered the mechanisms that enable Dengue virus to adapt and spread throughout the world, optimizing the virus and increasing the likelihood of outbreaks. Read More »

Longboat gives Greater Gift Initiative 980 vaccines

The Greater Gift Initiative (GGI) recently announced that it has received 980 vaccines by means of a donation from Longboat. Read More »

CSL gains exclusive rights to RAPIVAB

CSL Ltd. recently announced that it now has exclusive rights to commercialize RAPIVAB, the influenza treatment that was created by BioCryst Pharmaceuticals Inc. Read More »

Antibody response linked to decreased mother-to-child HIV transmission

Despite wide access to drug regimens and therapies that can interrupt transmission, an estimated 250,000 HIV infections each year worldwide are mother-to-child. Read More »

Medicago to construct new production facility in Canada

Medicago, a leading Canadian biotechnology company and an international developer and manufacturer of plant-based therapeutics and vaccines, recently announced that it will build a new production facility worth $245 million (USD) in Quebec City, Canada. Read More »

West Nile virus vaccine enters Phase I clinical trials

Researchers from the Oregon National Primate Research Center at Oregon Health & Science University (OHSU) recently started a Phase 1, first-in-human clinical trial for a West Nile virus vaccine at Duke University. Read More »

Research team makes promising discovery for HIV treatment

A team of researchers has discovered that the human immune system can manage large bursts of activity of HIV, suggesting that it may be possible to use a “kick and kill” strategy to treat and cure HIV. Read More »

Quintiles receives Best Clinical Research Organization award

Quintiles recently received the Best Clinical Research Organization (CRO) award in recognition of the company’s 2015 achievements. Read More »

Liquidia showcases PRINT vaccine technology at conference

Liquidia Technologies showcased the diverse abilities of its PRINT (Particle Replication In Non-Wetting Templates) technology in vaccine development at the 15th World Vaccines Congress this week in Washington, D.C. PRINT technology involves particle engineering and enables Liquidia to accurately tailor a specific particle’s shape, size, hydrophobicity, charge and composition. Read More »

Duke researchers receive grants for HIV vaccine studies

Researchers at Duke Medicine in North Carolina recently accepted a large, multi-year federal grant from the National Institutes of Health (NIH) for their projects to develop HIV vaccines. Read More »